REMARKS/ARGUMENTS

Claims 1, 2, 14 and 15 are active.

Claims 1 and 2 have been indicated as being allowed (see Office Action Summary box 5).

Claims 14 and 15 have been added defining the compounds represented by formula I in Claims 1 and 2 combined with a pharmaceutically acceptable carrier, which is described on page 30 of the present application.

The rejections of Claims 3-11 under 35 USC 112, first paragraph (both written description and enablement), of Claims 3-13 under 35 USC 112, second paragraph and of Claims 12-13 under 35 USC 103(a) citing Fujii *et al.* are no longer applicable as these claims have been cancelled. Withdrawal of the rejections is requested.

A Notice of Allowance is also requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 08/07) Daniel J. Pereira

Registration No. 45,518